Absorbent materials

Abstract
An absorbent material for use in wound dressings is provided. The absorbent material comprises a blend of a superabsorbent gel-forming fiber and a non gel-forming fiber, wherein the blend of fiber does not comprise a superabsorbent gel-forming fiber formed from a polysaccharide.
Description
CROSS REFERENCE TO RELATED APPLICATION

This application claims priority to GB Patent Application No. 1303971.4, which was filed on 6 Mar. 2013, the teachings of which are incorporated herein by reference.


The present invention relates to superabsorbent materials useful in the manufacture of absorbent articles such as wound dressings, and in particular wound dressings for the treatment of chronic, non-healing wounds.


Absorbent fibres useful as components in advanced wound care dressings are known in the art, particularly fibres based on alginic acid, carboxymethylcellulose (CMC), carboxymethylchitosan, cellulose ethyl sulfonate (CES) and salts thereof. Fibrous wound dressings may typically absorb up to 20-25 g of wound exudate per 100 cm2 dressing. Heavily exuding wounds such as diabetic leg ulcers may exude 5-10 g of liquid per 10 cm2 per 24 h. A wound of say 80 cm2 would therefore overwhelm a 100 cm2 fibrous wound dressing within a few hours, necessitating change of the dressing. To partly overcome this, superabsorbent materials are often used in advanced wound care dressings.


Standard superabsorbent materials, such as those based upon polyacrylic acid and its salts, soften and lose their mechanical strength when they absorb fluid and become wet. This is particularly undesirable when the material is intended for use as wound dressing where it may be necessary to remove a used dressing in one piece before it is replaced. A loss of mechanical strength may lead to break up of the dressing which may lead to complications, pain and discomfort for the patient and an extension of treatment time.


Powdered superabsorbent materials are used, often in combination with a bulking agent such as cellulose fluff, in absorbent wound dressings such as Sorbion Sachet S (Sorbion Gmbh & Co, Germany) and Vliwasorb, (Lohmann and Rauscher Gmbh & Co, Austria). In these dressings the poor mechanical strength of the superabsorbent powder when wet is overcome by enclosing the material in a non-woven outer pouch. The pouch may be made of a textile material of a soft texture, for example a perforated or mesh-type hydrophobic fleece-type film such as polyethylene or polypropylene film or a natural-fibre fabric or fleece. Dressings such as the Sorbion Sachet S and Vliwasorb dressings are also not suitable for use in cavity wounds. Due to the very large absorbent capacity of these dressings, on absorbing wound exudate they swell to many times their original dimension, potentially causing pain and trauma to the patient and extending treatment times. Dressings containing a superabsorbent material in the form of a powder may also disadvantageously exhibit gel blocking where the surface of a superabsorbent particle gels, preventing fluid transfer and leaving the inside of the particle dry. This may reduce the overall absorbency of the dressing and may potentially lead to harmful maceration of the periwound skin. Due to the very large absorbent capacity of these dressings they lack flexibility when wet.


Other wound dressings such as Askina Absorb+ (B. Braun Melsungen AG) and Sorbsan Plus SA (Aspen Medical, UK) seek to overcome this by using a superabsorbent fibre instead of a powdered material. Both contain a fabric comprising cellulose fluff pulp, superabsorbent fibre and a thermoplastic bicomponent fibre. The thermoplastic bicomponent fibre is used to fuse together the individual filaments of superabsorbent fibre and fluff pulp which would otherwise be unusably weak when wet. The superabsorbent fibres used in Askina Absorb+ are contained within a non-woven outer pouch that, prima facie, is not dissimilar to the type used in products such as Sorbion Sachet A or Vliwasorb. The superabsorbent fibres used in Sorbsan Plus SA, present in a multilaminar construction of a fabric comprising cellulose fluff pulp, superabsorbent fibre and a thermoplastic bicomponent fibre, are needle bonded to a wound contacting calcium alginate layer. The backing layer may comprise two outer layers which are a blend of fluff pulp and low melt binder, and a core absorbency layer which is a blend of fluff pulp, gel-forming polymer superabsorbent fibres and low melt binder. However, due to their multiple layers these dressings are very thick and inflexible, having a typical weight of 250-300 g/m2. Because of the large amount of non absorbent thermoplastic fibre in the cellulose fluff pulp, superabsorbent fibre and thermoplastic bicomponent fibre containing fabric, the absorbency per gram is relatively low, comparable to or only slightly better than that of conventional fibrous wound dressings.


Cotton in GB0905341.4 seeks to provide a method for reinforcing superabsorbent materials. A layered arrangement is formed with a single inner absorbent layer sandwiched between two outer reinforcing layers. Cotton discloses that the application of high frequency mechanical vibrations to the layered arrangement is able to bring about the generation of localised heat by friction. Because the layered arrangement contains a thermoplastic material that fuses when heated, the heat generated causes the welding of those layers together to form a composite absorbent material. This method of reinforcing an absorbent material relies on ultrasonically welding together at least two different fabrics, at least one of which contains a thermoplastic synthetic fibre. Synthetic thermoplastic fibres are disadvantageous in that they do not absorb fluid and in this application are adding mass and cost to the absorbent article without adding to the capability to absorb fluid.


It is an object of the present invention to mitigate at least some of the problems described above.


According to a first aspect of the present invention, there is provided an absorbent material comprising a blend of a superabsorbent gel-forming fibre and a non gel-forming fibre, wherein the blend of fibres does not comprise a superabsorbent gel-forming fibre formed from a polysaccharide.


According to a second aspect of the present invention, there is provided an absorbent material comprising a blend of fibres, the blend of fibres consisting of a single type of superabsorbent gel-forming fibre and a non gel-forming fibre.


By the term ‘blend’ it will be appreciated that the superabsorbent gel-forming fibres and the non gel-forming fibres are intimately mixed so as to form a homogenous mixture of fibres.


It will be understood that the statements below apply equally to the first and second aspects of the invention, unless stated otherwise.


The superabsorbent gel-forming fibre may be formed from a superabsorbent polymer. It will be understood that a superabsorbent polymer is a polymer which is capable of absorbing water in an amount as much as 500 times its own weight. In some embodiments, the superabsorbent polymer is capable of absorbing water in an amount of more than 10, more than 20, more than 30, more than 40, more than 60 or more than 100 times its own weight. In some embodiments, the super-absorbent gel-forming fibre is capable of absorbing at least 15, at least 20, at least 30, at least 50, at least 75 or at least 100 g of liquid (e.g. water or saline) per g of fibre. In some embodiments, the super-absorbent polymer is capable of absorbing more than 20, more than 40, more than 60, more than 80 or more than 100 g of liquid (e.g. water or saline) per gram of fibre.


In some embodiments, the superabsorbent polymer is a synthetic polymer. Suitable synthetic polymers may be prepared from polymerizable, unsaturated, acid-containing monomers, such as unsaturated carboxylic acids and acid anhydrides, unsaturated sulfonic acids and combinations thereof. Useful unsaturated carboxylic acid and carboxylic acid anhydride monomers include, e.g., acrylic acid, methacrylic acid, ethacrylic acid, chloroacrylic acid, cyanoacrylic acid, crotonic acid, phenylacrylic acid, acrytoxypropionic acid, sorbic acid, chlorosorbic acid, angelic acid, cinnamic acid, p-chlorocinnamic acid, stearylacrylic acid, itaconic acid, citraconic acid, mesaconic acid, glutaconic acid, aconitic acid, maleic acid, fumaric acid, tricarboxyethylene acid anhydride, maleic acid anhydride, and combinations thereof.


Useful unsaturated sulfonic acid monomers for the preparation of synthetic superabsorbent polymers include aliphatic and aromatic vinyl sulfonic acids (e.g., vinylsulfonic acid, allyl sulfonic acid, vinyl toluene sulfonic acid and styrene sulfonic acid), acrylic and methacrylic sulfonic acids (e.g., sulfoethyl acrylate, sulfoethyl methacrylate, sulfopropyl acrylate, sulfopropyl methacrylate, 2-hydroxy-3-methacryloxypropyl sulfonic acid and 2-acrylamide-2-methylpropane sulfonic acid), and combinations thereof.


In some embodiments, the superabsorbent polymer is selected from the group consisting of: polyacrylates or co-polymers thereof; polymers of anhydrides, such as poly(maleic anhydride), or co-polymers thereof; polymers with carboxylic acid groups or salts thereof, such as polymers of acrylic acid, maleic acid, methacrylic acid or derivatives thereof; polymers of acrylamide (e.g. polyacrylamide) or co-polymers thereof; polyethylene oxide (PEO); polyvinyl alcohol (PVOH); graft co-polymers; or mixtures thereof. Suitable polymers of acrylamide or copolymers thereof include polyacrylamide, polyAMPs (poly-acrylamido-2-methylpropane sulfonic acid) or its sodium salt, and acrylamide-co-acrylic acid.


In some embodiments, the superabsorbent polymer is a polyacrylate or copolymer thereof. Polyacrylates are a broad group of synthetic polymers derived from monomers which include esters of acrylic acid, for example poly(hydroxyl methacrylate), and salts of polymers of acrylic acid and derivatives thereof.


Suitable polyacrylates or copolymers thereof for use in the invention include sodium polyacrylate, sodium polymethacrylate, and co-polymers of acrylic acid with other monomers. Further examples include co-polymers of acrylic acid with vinyl pyrrolidone monomers, optionally with a diacrylate cross-linker, co-polymers of acrylic acid with maleic acid or hydrolysed maleic anhydride. Co-polymers may also comprise olefins, such as ethylene.


In some embodiments the polymers or co-polymers are cross-linked.


One example of polyacrylate fibres is ‘SAF’™, commercially available fibres sold by Technical Absorbent Limited (Grimsby, UK). SAF™ is formed from a cross-linked polymer of acrylic acid (AA) methylacrylate (MA) and a small quantity of special acrylate/methylacrylate monomer (SAMM) in which the acrylic acid is partially neutralised to the sodium salt of acrylic acid (AANa). SAF™ fibres are available in different staple lengths, linear density and with different degrees of cross linking to give different absorbency levels. Thus, in some embodiments the superabsorbent gel-forming fibre is SAF.


In some embodiments of the second aspect of the invention, the superabsorbent gel-forming fibre is formed from a graft polymer. Graft polymers are polymers grafted onto a backbone of another suitable polymer, such as a polysaccharide backbone. The graft polymer may be a homopolymer or a copolymer. Suitable polymers for the formation of graft polymers include polyacrylic acid or acrylamide-co-acrylic acid. These polymers may be grafted on to a backbone of chitosan, cellulose, starch, guar gum, carrageenan, alginate, or synthetic polymers such as PVOH.


In some embodiments of the second aspect of the invention, the superabsorbent gel-forming fibre is formed from a polysaccharide. Suitable polysaccharides include alginate (i.e. a salt of alginic acid), modified cellulose, modified chitosan, guar gum, carrageenan, pectin, starch or mixtures thereof. The term ‘modified’ will be understood as meaning that the polysaccharide molecules have been chemically modified, for example by covalent attachment of additional functional groups. Examples of modified cellulose include carboxymethylcellulose (CMC), cellulose ethyl sulfonate (CES) and cellulose ethyl sulfonate. Examples of modified chitosan include carboxymethylchitosan, ethyl sulfonated chitosan and carboxyethyl chitosan.


In some embodiments of the second aspect of the invention, the superabsorbent gel-forming fibre is not formed from modified cellulose. In some embodiments, the superabsorbent gel-forming fibre is not formed from CES. In some embodiments, the superabsorbent gel-forming fibre is not formed from alginate. In further embodiments, the superabsorbent gel-forming fibre is not formed from a polysaccharide.


In some embodiments, the non gel-forming fibre is a naturally occurring fibre, for example cotton. In other embodiments the non gel-forming fibres are semi-synthetic fibres, in particular semi-synthetic cellulose-based fibres such as rayon (otherwise known as ‘viscose’ or ‘viscose-rayon’) or lyocell fibres (formed from solvent spun non-modified cellulose). In other embodiments the non gel-forming fibres are (entirely) synthetic fibres such as nylon fibres (made from polyamides), acrylic fibres (made from polyacetonitriles), or fibres made from polyester or polyolefins (e.g. polypropylene, polyethylene), or co-polymers thereof.


In some particular embodiments, the non gel-forming fibres are lyocell fibres. These may be obtained by an organic solvent spinning process, for example using various amine oxides as solvents. In particular, N-methylmorpholine-N-oxide (“NMNO”) with water (about 12%) proves to be a particularly useful solvent. Examples of processes for preparing cellulose fibres are described in McCorsley et al., U.S. Pat. Nos. 4,142,913; 4,144,080; 4,211,574; 4,246,221; and 4,416,698, and others. Jurkovic et al., U.S. Pat. No. 5,252,284 and Michels et al., U.S. Pat. No. 5,417,909 deal especially with the geometry of extrusion nozzles for spinning cellulose dissolved in NMMO. Brandner et al., U.S. Pat. No. 4,426,228 is exemplary of a considerable number of patents that disclose the use of various compounds to act as stabilizers in order to prevent cellulose and/or solvent degradation in the heated NMMO solution. Franks et al., U.S. Pat. Nos. 4,145,532 and 4,196,282, deal with the difficulties of dissolving cellulose in amine oxide solvents and of achieving higher concentrations of cellulose. All of these patents are incorporated herein by reference. Lyocell fibres are commercially available under the brand name ‘TENCEL’® from Lenzing AG, Austria. Thus, in some embodiments the non gel-forming fibre is TENCEL.


The use of naturally occurring non gel-forming fibres, in particular semi-synthetic fibres such as those based on cellulose, is advantageous because these fibres provide strength while also being capable of absorbing liquid. In some embodiments, the material does not contain any (entirely) synthetic non gel-forming fibres (i.e. the blend of fibres consists of naturally occurring and/or semi-synthetic fibres only). These embodiments are particularly advantageous since there are no non absorbent fibres in the material, thereby maximising the absorbency per gram of material.


In some embodiments, the non gel-forming fibre (in fibre form) is capable of absorbing more than 0.5, more than 0.8, more than 1.0, more than 1.2, more than 1.5 or more than 2.0 g liquid per gram of fibre. In some embodiments, the non gel-forming fibre (in fibre form) is capable of absorbing approximately 1 g of liquid per g of fibre.


In some embodiments, the superabsorbent gel-forming fibre is a polyacrylate (e.g. SAF) and the non gel-forming fibre is a semi-synthetic fibre. In particular embodiments, the superabsorbent gel-forming fibre is polyacrylate (e.g. SAF) and the non gel-forming fibre is a lyocell fibre such as TENCEL.


In some embodiments, the absorbent material comprises at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% of the superabsorbent gel-forming fibre, by weight of the total fibre content of the material. In some embodiments, the absorbent material comprises no more than 90%, no more than 80%, no more than 70%, no more than 60%, no more than 50% or no more than 40% of the superabsorbent gel-forming fibre, by weight of the total fibre content of the material.


In some embodiments, the absorbent material comprises at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or at least 60% of the non gel-forming fibre, by weight of the total fibre content of the material. In some embodiments, the absorbent material comprises no more than 70%, no more than 60%, no more than 50%, no more than 40%, no more than 30% or no more than 20% of the superabsorbent gel-forming fibre, by weight of the total fibre content of the material.


In further embodiments, the absorbent material comprises from 30 to 90% or from 40% to 60% of the superabsorbent gel-forming fibre and from 10 to 70% or from 60% to 40% of the non gel-forming fibre, by weight of the total fibre content of the material. In particular embodiments, the material comprises 50% the superabsorbent gel-forming fibre and 50% of the non gel-forming fibre.


In some embodiments, the absorbent material has a weight of no more than 500 g/m2, no more than 400 g/m2, no more than 300 g/m2, no more than 200 g/m2, no more than 150 g/m2, no more than 120 g/m2, no more than 100 g/m2, no more than 80 g/m2, no more than 60 g/m2, no more than 50 g/m2 or no more than 40 g/m2.


In some embodiments, the absorbent material has an absorbency of more than 18, more than 19, more than 20, more than 22, more than 24, more than 26 or more than 28 grams of liquid (water or saline) per gram of material.


The absorbent material of the invention may be in sheet form. In some embodiments, the material is non-woven. The material may be made by carding, air-laying and/or needle-bonding the fibres, or by or hydro-entangling the fibres using a non-aqueous solvent. In some embodiments, the absorbent material is made by a method comprising carding and, optionally, needle bonding the fibres. Such methods are well-known to those skilled in the art.


The absorbent material may comprise one or more optional ingredients such as preservatives, antimicrobial agents or other pharmacologically active agents. For example, antibiotics (e.g. penicillin), antimicrobial agents (such as silver, PHMB (polyhexamethylene biguanide)), antiseptic agents (e.g. povidone iodine), anti-inflammatory agents (such as hydrocortisone), or other agents (such as zinc oxide) may be included. Such optional agents may be applied to the absorbent material or article by spraying, coating, dipping or by any other method known to those skilled in the art.


According to a third aspect of the present invention there is provided an absorbent article comprising the absorbent material according to the first aspect of the invention.


Absorbent articles may include wound dressings, disposable sanitary articles such as nappies (diapers), disposable nappies and training pants, feminine care products, e.g., tampons, sanitary towels, or napkins and pant liners, and incontinence products. In particular embodiments, the present invention provides a wound dressing comprising the absorbent material in accordance with the first or second aspects of the invention.


In some embodiments, the wound dressing may be in the form of swabs, wound pads, wadding ribbons, sponges, nets and bandages.


The absorbent material of the first aspect of the invention may form one of a plurality of layers. Thus in some embodiments, the wound dressing is a multi-laminar dressing, which may comprise at least 2 or at least 3 layers. Multi-laminar dressings comprising the absorbent material of the invention are more flexible and more absorbent than commercially available multi-laminar dressings, and thus offer improved comfort for the patient. They are also more convenient to use since a single, multi-laminar dressing is simpler and quicker for a care giver to apply to a wound than multiple separate components.


In some embodiments, the wound dressing comprises a first layer comprising or consisting of the absorbent material of the first aspect of the present invention, and a second layer formed from any suitable material. The material of the second layer may be selected according to its desired function. For example, the second layer may provide absorbency, padding, water-proofing or support. A variety of suitable wound dressing materials are commercially available and will be known to those skilled in the art. In some embodiments, the second layer is formed from another, known, absorbent material (such as alginate), which advantageously increases the absorbency of the dressing. In further embodiments, the wound dressing comprises the absorbent material of the first aspect of the present invention bonded to a foam layer. The foam may be a hydrophilic foam such as that described in EP2498829.


In some embodiments, the wound dressing comprises three layers. In some particular embodiments, the wound dressing comprises two outer layers and an inner core, wherein the inner core comprises or consists of the absorbent material of the first aspect of the invention. The outer layers may comprise any suitable material, for example alginate, foam, CES, CMC, or cellulose fluff pulp and a suitable binder. The outer layers may form wound contacting layers. The three-layer combination is useful as a ribbon dressing for cavity wounds. By providing two wound contacting layers and a core layer formed from the absorbent material of the first aspect of the present invention, the absorbency of the dressing is increased compared to existing technology.


In some embodiments, the wound dressing additionally comprises a wound contact layer. The contact layer is the layer which comes into contact with the surface (e.g. of the skin or wound) to which the material is applied. The contact layer conveniently increases the absorbency of the material, and may also help to prevent the material from sticking to the surface. The contact layer may also offer further advantages including providing a moist environment and/or delivering therapeutics or other agents, for example agents conducive to wound healing.


In some embodiments, the wound contact layer is a non-woven or a perforated polymer film, which is applied to one or more surfaces of the dressing. In some embodiments, the wound contact layer comprises or consists of alginate, such as calcium or silver alginate.


In some embodiments, the wound contact layer comprises or consists of alginate, modified cellulosic fibres (such as carboxymethyl cellulose (CMC) or cellulose ethyl sulfonate (CES), hydrogels or foams (e.g. polyurethane, alginate, cellulosic or modified cellulosic foams). Suitable hydrogels may include cross-linked hydrophobic polymers. The polymers may be polysaccharides (e.g. alginates, gelatins, pectins) or synthetic polymers (e.g. polymers based on 2-acrylamido-2-methylpropane sulfonic acid (AMPS), PEG, PVP, PVOH etc.). Suitable hydrogels are commercially available, for example, from Lohmann & Rauscher.


In some embodiments, the wound contact layer comprises or consists of alginate. The alginate salt may comprise a monovalent cation or a multivalent cation, in particular a divalent cation provided that the divalent cation is not Mg2+. In some embodiments, the alginate is calcium alginate, sodium calcium alginate, sodium alginate, silver alginate, copper alginate or mixtures thereof. In some embodiments, the alginate is calcium alginate.


Alginate fibres with a range of M/G ratios (the ratio of D-mannuronate to L-guluronate) may be used. A suitable range of M content in the M:G ratio is 30:70 and more preferably 40:60.


The absorbent material of the invention may be attached or bonded to the other materials or layers (such as a wound contact layer) in a multi-laminar wound dressing by any suitable means, such as needle punching, thermal bonding, ultrasonic welding, sewing, stitch bonding, adhesive etc. Such techniques will be well known to those skilled in the art.


Embodiments of the present invention will now be described by way of example only.







EXAMPLES
Example 1
Absorbency

SAF (Technical Absorbents, Grimsby, UK), was carded with TENCEL fibres (Lenzing Fibres, Grimsby, UK) using a sample card and cross folder to produce a carded web. This carded web was needle punched using a TexTex needle loom to give materials A, B and C. Absorbency was measured by weighing a 5 cm×5 cm piece of sample material (W1). Next, the sample was placed in Solution A (16.6 g NaCl and 0.74 g CaCl2.2H2O in 2 L water) at 37° C. for 30 minutes in a petri dish. Then, the square was lifted out of the petri-dish by holding the square by one corner, and the sample was allowed to drain for 30 seconds. The sample was then reweighed to obtain the end weight (W2). The fabric absorbency is given by ((W2−W1)/W1).


The retention value of the material was determined for each sample immediately following the absorbency test.


After recording the weight of the sample in the petri dish absorbency test, the sample was placed on blue paper roll (eight layers). A perspex sheet weighing 1358 g and considered to be equivalent to pressure equal to 40 mmHg was placed on top for 30 seconds and then removed. The sample was removed using forceps and weighed. The retention value was determined according to the formula ((W3−W1)/W1) where W3 is the wet weight after compression and W1 is the dry weight.


The absorbency and retention values were measured for the following materials and the results shown in Table 1 below:

  • A: 40:60 SAF:TENCEL (120 g/m2)
  • B: 50:50 SAF:TENCEL (120 g/m2)
  • C: 60:40 SAF:TENCEL (120 g/m2)
  • D: Calcium alginate
  • E: DURAFIBER
  • F: AQUACEL Extra
















TABLE 1







A
B
C
D
E
F






















g/g
Absorbency
20
30
23
16
18
12



Retention
12
17
15
 6
11
 6









It can be seen from the data above that at a ratio of 40:60 or 60:40 SAF:Tencel (by weight), both the absorbency and the retention values of the material were improved compared to calcium alginate and other commercial wound dressing products. It was surprisingly observed that at a ratio of 50:50 SAF:Tencel (by weight), both the absorbency and the retention values were significantly increased.


Example 2
Tensile Strength

The tensile strength of materials A-F when wet was measured using the following protocol. The results are shown in Table 2 below.

  • 1. Cut samples in the cross direction (CD)/machine direction (MD) to 10 cm×2.5 cm.
  • 2. Draw a line at 2.5 cm from each end of the sample across the width to give a 5 cm marked section in the middle.
  • 3. Using a Universal Testing Machine (such as those made by Instron), mount the sample so that the edge of each jaw is on the line marked on the fabric
  • 4. Apply 2.5 ml of solution A slowly to the section of fabric between the jaws:
  • 5. Allow to stand for 1 minute.
  • 6. The cross head speed is set to 100 mm/min. Start test and allow the samples to extend to break.
  • 7. Stop test. Remove sample. Return cross head to start position.
  • 8. The software calculates the breaking load, extension and tensile strength in N/cm.















TABLE 2





Wet








Tensile








strength








(N/cm)
A
B
C
E
F
G





















MD
11.3
 8.0
7.0
1.0
2.5
2.4


CD
18.7
19.5
8.8
1.9
3.8
7.2









It can be seen from the data in Table 2 that the wet tensile strength of the SAF: TENCEL blends (materials A, B and C) was significantly increased in both the machine direction and the cross direction compared to the known materials. The wet tensile strength of the 50:50 SAF:TENCEL blend was more than 3-fold greater in the machine direction, and more than 2.5-fold greater in the cross direction, than that of the commercial wound dressings (F and G). Surprisingly, the wet tensile strength of the 40:60 SAF:TENCEL blend in the machine direction was more than 4-fold greater than that of the commercial products and more than 10-fold greater than that of the calcium alginate.

Claims
  • 1. An absorbent material comprising a blend of a superabsorbent gel-forming fibre and a non gel-forming fibre, wherein the blend of fibres does not comprise a superabsorbent gel-forming fibre formed from a polysaccharide, wherein the non gel-forming fibre is a semi-synthetic fibre, and wherein the absorbent material consists of 50% of the superabsorbent gel-forming fibre and 50% of the non gel-forming fibre by weight of the total fibre content of the material; and wherein the superabsorbent gel-forming fibre is formed from a cross-linked polymer of acrylic acid (AA), methylacrylate (MA) and special acrylate/methylacrylate monomer (SAMM) and wherein the non gel-forming fibre is lyocell fibre.
  • 2. An absorbent material according to claim 1, wherein the material has an absorbency of more than 18 grams of liquid per gram of material.
  • 3. A wound dressing comprising the absorbent material according to claim 1.
  • 4. The absorbent material according to claim 1, wherein the material is in the form of a non-woven sheet.
  • 5. The absorbent material according to claim 4, wherein the material is formed by needle-bonding the fibres.
  • 6. The wound dressing according to claim 3, wherein the wound dressing comprises a wound contact layer comprising or consisting of a polysaccharide.
Priority Claims (1)
Number Date Country Kind
1303971.4 Mar 2013 GB national
US Referenced Citations (383)
Number Name Date Kind
4142913 McCorsley, III et al. Mar 1979 A
4144080 McCorsley, III Mar 1979 A
4145532 Franks et al. Mar 1979 A
4196282 Franks et al. Apr 1980 A
4211574 McCorsley, III et al. Jul 1980 A
4246221 McCorsley, III Jan 1981 A
4416698 McCorsley, III Nov 1983 A
4426228 Brandner et al. Jan 1984 A
4865596 Weisman et al. Sep 1989 A
5252284 Jurkovic et al. Oct 1993 A
5311389 Howey May 1994 A
5366832 Hayashi et al. Nov 1994 A
5417909 Michels et al. May 1995 A
5599585 Cohen Feb 1997 A
5656355 Cohen Aug 1997 A
5814094 Flick et al. Sep 1998 A
5848995 Walder Dec 1998 A
5985301 Nakamura et al. Nov 1999 A
6087549 Flick et al. Jul 2000 A
6113636 Ogle Sep 2000 A
6190407 Ogle Feb 2001 B1
6191335 Robinson Feb 2001 B1
6194332 Rock et al. Feb 2001 B1
6218910 Miller Apr 2001 B1
6224898 Balogh et al. May 2001 B1
6267782 Ogle Jul 2001 B1
6281515 Demeo et al. Aug 2001 B1
6459091 Demeo et al. Oct 2002 B1
6501343 Miller Dec 2002 B2
6576338 Meijer et al. Jun 2003 B1
6582411 Carstens Jun 2003 B1
6592888 Jensen et al. Jul 2003 B1
6599523 Cohen Jul 2003 B2
6602811 Rock et al. Aug 2003 B1
6627785 Cohen Sep 2003 B1
6630016 Koslow Oct 2003 B2
6660172 Koslow Dec 2003 B2
6686754 Miller Feb 2004 B2
6692773 Burrell et al. Feb 2004 B2
6716895 Terry Apr 2004 B1
6719987 Langford et al. Apr 2004 B2
6720006 Hanke et al. Apr 2004 B2
6723350 Bowlby et al. Apr 2004 B2
6723428 Foss et al. Apr 2004 B1
6822034 Bast et al. Nov 2004 B2
6828578 Demeo et al. Dec 2004 B2
6835311 Koslow Dec 2004 B2
6841244 Foss et al. Jan 2005 B2
6841791 Demeo et al. Jan 2005 B2
6861570 Flick et al. Mar 2005 B1
6866704 Koslow Mar 2005 B2
6872311 Koslow Mar 2005 B2
6905711 Tullo et al. Jun 2005 B1
6911437 Cohen Jun 2005 B2
6913154 Koslow Jul 2005 B2
6917210 Miller Jul 2005 B2
6939568 Burrell et al. Sep 2005 B2
6946196 Foss et al. Sep 2005 B2
6949598 Terry Sep 2005 B2
6953604 Koslow Oct 2005 B2
6959820 Koslow Nov 2005 B2
6979491 Yan et al. Dec 2005 B2
6989156 Gillis Jan 2006 B2
6989157 Gillis et al. Jan 2006 B2
6998058 Koslow Feb 2006 B2
7001617 Burrell et al. Feb 2006 B2
7005556 Flick et al. Feb 2006 B1
7008537 Koslow Mar 2006 B2
7008647 Burrell et al. Mar 2006 B2
7011753 Koslow Mar 2006 B2
7019391 Tran Mar 2006 B2
7078060 Burrell et al. Jul 2006 B2
7087249 Burrell et al. Aug 2006 B2
7118761 Canada et al. Oct 2006 B2
7141518 MacDonald et al. Nov 2006 B2
7144533 Koslow Dec 2006 B2
7179849 Terry Feb 2007 B2
7201925 Gillis Apr 2007 B2
7214847 Flick et al. May 2007 B1
7229689 Qin et al. Jun 2007 B2
7230153 Flick et al. Jun 2007 B2
7241388 Koslow Jul 2007 B2
7255881 Gillis et al. Aug 2007 B2
7276166 Koslow Oct 2007 B2
7287650 Koslow Oct 2007 B2
7291762 Flick et al. Nov 2007 B2
7296691 Koslow Nov 2007 B2
7300673 Djokic Nov 2007 B2
7330369 Tran Feb 2008 B2
7375417 Tran May 2008 B2
7378156 Terry May 2008 B2
7410650 Lin Aug 2008 B2
7427416 Gillis et al. Sep 2008 B2
7455854 Gower et al. Nov 2008 B2
7462753 Yu et al. Dec 2008 B2
7470437 Burrell et al. Dec 2008 B2
7476889 Demeo et al. Jan 2009 B2
7489537 Tran Feb 2009 B2
7514248 Gower et al. Apr 2009 B2
7514249 Gower et al. Apr 2009 B2
7544496 Gower et al. Jun 2009 B2
7547449 Gower et al. Jun 2009 B2
7630227 Tran Dec 2009 B2
7655112 Koslow Feb 2010 B2
7671398 Tran Mar 2010 B2
7687076 Djokic Mar 2010 B2
7745509 Burton et al. Jun 2010 B2
7775998 Riesinger Aug 2010 B2
7842306 Cowan et al. Nov 2010 B2
7862624 Tran Jan 2011 B2
7864560 Tran Jan 2011 B2
7951853 Ismail et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7989674 Flick et al. Aug 2011 B2
7998504 Djokic Aug 2011 B2
8021685 Cowan et al. Sep 2011 B2
8034454 Terry et al. Oct 2011 B2
8056733 Koslow Nov 2011 B2
8084762 Tran Dec 2011 B2
8093444 Flick et al. Jan 2012 B2
8118791 Flick et al. Feb 2012 B2
8118792 Effing et al. Feb 2012 B2
8118793 Effing et al. Feb 2012 B2
8123730 Effing et al. Feb 2012 B2
8124826 Greenhalgh et al. Feb 2012 B2
8183167 Delattre et al. May 2012 B1
8187626 Cohen May 2012 B2
8193267 Burton et al. Jun 2012 B2
8217220 Abbas et al. Jul 2012 B2
8283513 Flick et al. Oct 2012 B2
8293964 Flick et al. Oct 2012 B2
8334524 Demeo et al. Dec 2012 B2
8343535 Burd et al. Jan 2013 B2
8361553 Karandikar Jan 2013 B2
8367089 Wan et al. Feb 2013 B2
8394403 Cowan et al. Mar 2013 B2
8449514 Flick et al. May 2013 B2
8450716 Tran May 2013 B2
8455710 Flick et al. Jun 2013 B2
8461410 Addison et al. Jun 2013 B2
8613363 Koslow Dec 2013 B2
20010035800 Miller Nov 2001 A1
20010055622 Langford et al. Dec 2001 A1
20020012693 Cohen Jan 2002 A1
20020043631 Demeo et al. Apr 2002 A1
20020051824 Burrell et al. May 2002 A1
20020064551 Cohen May 2002 A1
20020082340 Bast et al. Jun 2002 A1
20020099449 Speitling et al. Jul 2002 A1
20020122832 Hanke et al. Sep 2002 A1
20020172709 Nielsen et al. Nov 2002 A1
20020182265 Bowlby et al. Dec 2002 A1
20020192298 Burrell et al. Dec 2002 A1
20030010939 Demeo et al. Jan 2003 A1
20030021854 Burrell et al. Jan 2003 A1
20030049300 Terry Mar 2003 A1
20030054046 Burrell et al. Mar 2003 A1
20030067316 Miller Apr 2003 A1
20030072810 Burrell Apr 2003 A1
20030086977 Gillis May 2003 A1
20030099718 Burrell et al. May 2003 A1
20030130638 Baker Jul 2003 A1
20030140785 Koslow Jul 2003 A1
20030141261 Koslow Jul 2003 A1
20030153889 Gibbs Aug 2003 A1
20030168401 Koslow Sep 2003 A1
20030170314 Burrell et al. Sep 2003 A1
20030170453 Foss et al. Sep 2003 A1
20030177909 Koslow Sep 2003 A1
20030180346 Woods Sep 2003 A1
20030180378 Gillis et al. Sep 2003 A1
20030180379 Burrell et al. Sep 2003 A1
20030185889 Cheng et al. Oct 2003 A1
20030185901 Burrell et al. Oct 2003 A1
20030190851 Yan et al. Oct 2003 A1
20030194444 Burrell et al. Oct 2003 A1
20030196963 Koslow Oct 2003 A1
20030196964 Koslow Oct 2003 A1
20030200868 Koslow Oct 2003 A1
20030201231 Koslow Oct 2003 A1
20030203046 Burrell et al. Oct 2003 A1
20030205529 Koslow Nov 2003 A1
20030205530 Koslow Nov 2003 A1
20030205531 Koslow Nov 2003 A1
20030206944 Cohen Nov 2003 A1
20030206966 Burrell et al. Nov 2003 A1
20030213750 Koslow Nov 2003 A1
20030232071 Gower et al. Dec 2003 A1
20040001880 Bowler et al. Jan 2004 A1
20040004196 Demeo et al. Jan 2004 A1
20040030276 Flick et al. Feb 2004 A1
20040031749 Koslow Feb 2004 A1
20040038609 Mayer Feb 2004 A1
20040049145 Flick et al. Mar 2004 A1
20040084378 Koslow May 2004 A1
20040116551 Terry Jun 2004 A1
20040129112 Gillis Jul 2004 A1
20040131562 Gower et al. Jul 2004 A1
20040131698 Gillis et al. Jul 2004 A1
20040140822 Miller Jul 2004 A1
20040157073 Bowlby et al. Aug 2004 A1
20040176312 Gillis Sep 2004 A1
20040178142 Koslow Sep 2004 A1
20040191329 Burrell et al. Sep 2004 A1
20040191500 Foss et al. Sep 2004 A1
20040197553 Foss et al. Oct 2004 A1
20040202860 Foss et al. Oct 2004 A1
20040209059 Foss et al. Oct 2004 A1
20040214495 Foss et al. Oct 2004 A1
20040229034 Djokic Nov 2004 A1
20040234604 Mecking et al. Nov 2004 A1
20040241213 Bray Dec 2004 A1
20050003728 Foss et al. Jan 2005 A1
20050008861 Yadav et al. Jan 2005 A1
20050011827 Koslow Jan 2005 A1
20050019568 Foss et al. Jan 2005 A1
20050035327 Canada et al. Feb 2005 A1
20050037057 Schuette et al. Feb 2005 A1
20050037058 Cowan et al. Feb 2005 A1
20050037680 Canada et al. Feb 2005 A1
20050051487 Koslow Mar 2005 A1
20050058835 Bayston et al. Mar 2005 A1
20050064020 Schuette et al. Mar 2005 A1
20050085144 Fish et al. Apr 2005 A1
20050101213 Foss et al. May 2005 A1
20050101900 Qin et al. May 2005 A1
20050106390 Foss et al. May 2005 A1
20050124724 Burton et al. Jun 2005 A1
20050129624 Burrell et al. Jun 2005 A1
20050136100 Foss et al. Jun 2005 A1
20050136128 Gillis et al. Jun 2005 A1
20050147657 Canada et al. Jul 2005 A1
20050152990 Gower et al. Jul 2005 A1
20050191355 Foss et al. Sep 2005 A1
20050211930 Demeo et al. Sep 2005 A1
20050218397 Tran Oct 2005 A1
20050218398 Tran Oct 2005 A1
20050228351 Bourgeois et al. Oct 2005 A1
20050229328 Tran Oct 2005 A1
20050230822 Tran Oct 2005 A1
20050231855 Tran Oct 2005 A1
20050244484 Flick et al. Nov 2005 A1
20050271743 Burrell et al. Dec 2005 A1
20060057191 Wellinghoff Mar 2006 A1
20060083777 Burrell et al. Apr 2006 A1
20060083792 Gillis et al. Apr 2006 A1
20060115541 Gillis et al. Jun 2006 A1
20060127462 Cowan et al. Jun 2006 A1
20060141015 Tessier et al. Jun 2006 A1
20060145326 Tran Jul 2006 A1
20060149182 Addison et al. Jul 2006 A1
20060159732 Greenhalgh et al. Jul 2006 A1
20060160448 Abraham et al. Jul 2006 A1
20060198209 Tran Sep 2006 A1
20060202382 Lin Sep 2006 A1
20060204580 Cheng et al. Sep 2006 A1
20060204581 Cheng et al. Sep 2006 A1
20060204591 Burrell et al. Sep 2006 A1
20060240067 Chartier et al. Oct 2006 A1
20060260674 Tran Nov 2006 A1
20060264796 Flick et al. Nov 2006 A1
20060283567 Bauer et al. Dec 2006 A1
20070003603 Cornell et al. Jan 2007 A1
20070009586 Cohen Jan 2007 A1
20070051366 Hannsman et al. Mar 2007 A1
20070060691 Kim Mar 2007 A1
20070087023 Ismail et al. Apr 2007 A1
20070098806 Ismail et al. May 2007 A1
20070100269 Greenhalgh et al. May 2007 A1
20070122462 Chandra et al. May 2007 A1
20070134307 Robb et al. Jun 2007 A1
20070148449 Winterhalter Jun 2007 A1
20070179522 Flick et al. Aug 2007 A1
20070207335 Karandikar et al. Sep 2007 A1
20070218298 Terry Sep 2007 A1
20070243380 Hayhurst et al. Oct 2007 A1
20070259196 Ruhle et al. Nov 2007 A1
20070275043 Bradford et al. Nov 2007 A1
20070286895 Bowler et al. Dec 2007 A1
20070293799 Yu et al. Dec 2007 A1
20070298064 Koslow Dec 2007 A1
20080004559 Riesinger Jan 2008 A1
20080009812 Riesinger Jan 2008 A1
20080014286 Gillis et al. Jan 2008 A1
20080033506 Flick et al. Feb 2008 A1
20080053922 Bumin et al. Mar 2008 A1
20080064997 Flick et al. Mar 2008 A1
20080075650 Djokic Mar 2008 A1
20080075860 Djokic Mar 2008 A1
20080096449 Bourgeois et al. Apr 2008 A1
20080102122 Khanolkar et al. May 2008 A1
20080114279 Flick et al. May 2008 A1
20080119773 Flick et al. May 2008 A1
20080125687 Flick et al. May 2008 A1
20080199536 Terry Aug 2008 A1
20080199623 Terry Aug 2008 A1
20080213394 Ismail et al. Sep 2008 A1
20080233161 Djokic Sep 2008 A1
20080239791 Tran Oct 2008 A1
20080241229 Li et al. Oct 2008 A1
20080241795 Block et al. Oct 2008 A1
20080249453 Effing et al. Oct 2008 A1
20080249485 Effing et al. Oct 2008 A1
20080249486 Effing et al. Oct 2008 A1
20080286346 Effing et al. Nov 2008 A1
20080299160 Agboh et al. Dec 2008 A1
20090000007 Demeo et al. Jan 2009 A1
20090004474 Luo Jan 2009 A1
20090035342 Cornell et al. Feb 2009 A1
20090081312 Block et al. Mar 2009 A1
20090114857 Demeo et al. May 2009 A1
20090116277 Tran May 2009 A1
20090130160 Dugan May 2009 A1
20090214771 Kang et al. Aug 2009 A1
20090220560 Wan et al. Sep 2009 A1
20090247973 Yeh et al. Oct 2009 A1
20090252861 Tessier et al. Oct 2009 A1
20090259157 Thomas Oct 2009 A1
20090263468 Abbott et al. Oct 2009 A1
20090275906 Abbas et al. Nov 2009 A1
20090293882 Terry Dec 2009 A1
20100003296 Cheng et al. Jan 2010 A1
20100015208 Kershaw et al. Jan 2010 A1
20100021552 Hayes et al. Jan 2010 A1
20100042034 Riesinger Feb 2010 A1
20100044289 Koslow Feb 2010 A1
20100055157 Gunn Mar 2010 A1
20100073995 Tran Mar 2010 A1
20100098949 Burton et al. Apr 2010 A1
20100113871 Franken et al. May 2010 A1
20100124861 Wendler May 2010 A1
20100155692 Tran Jun 2010 A1
20100196448 Burd et al. Aug 2010 A1
20100221311 Cohen Sep 2010 A1
20100221312 Cohen Sep 2010 A1
20100233245 Narayana Sep 2010 A1
20100233273 Burton et al. Sep 2010 A1
20100262096 Hall Oct 2010 A1
20100291174 Barcikowski et al. Nov 2010 A1
20100291184 Clark et al. Nov 2010 A1
20110034894 Riesinger Feb 2011 A1
20110040289 Cowan et al. Feb 2011 A1
20110052698 Benoit et al. Mar 2011 A1
20110091557 Buckley et al. Apr 2011 A1
20110110141 Tran May 2011 A1
20110110999 Bogana et al. May 2011 A1
20110115512 Miller May 2011 A1
20110123597 Cohen May 2011 A1
20110135846 Seino et al. Jun 2011 A1
20110142898 Fan Jun 2011 A1
20110152843 Lundahl et al. Jun 2011 A1
20110171321 Luchsinger et al. Jul 2011 A1
20110189287 Abbott et al. Aug 2011 A1
20110232653 Imashiro et al. Sep 2011 A1
20110262556 Brooks et al. Oct 2011 A1
20110272619 Wang et al. Nov 2011 A1
20110275513 Tian et al. Nov 2011 A1
20110280928 Cowan et al. Nov 2011 A1
20110306699 Whang et al. Dec 2011 A1
20110313373 Riesinger Dec 2011 A1
20120034432 Cotton Feb 2012 A1
20120064138 Beveridge et al. Mar 2012 A1
20120091429 Tran Apr 2012 A1
20120094120 Foss et al. Apr 2012 A1
20120107592 Griesser et al. May 2012 A1
20120143157 Riesinger Jun 2012 A1
20120164449 Foss Jun 2012 A1
20120183674 Bonn-Savage et al. Jul 2012 A1
20120202043 Bonn-Savage et al. Aug 2012 A1
20120222826 Foss Sep 2012 A1
20120276205 Weissman et al. Nov 2012 A1
20120282321 Cohen Nov 2012 A1
20120299175 Tran Nov 2012 A1
20130052256 Smith Feb 2013 A1
20130066288 Lin Mar 2013 A1
20130122321 Karandikar et al. May 2013 A1
20130152309 Bray Jun 2013 A1
20130163310 Tran Jun 2013 A1
20130197460 Shaw et al. Aug 2013 A1
20130211308 Wan et al. Aug 2013 A1
20130216598 Wang et al. Aug 2013 A1
20130217649 Woods Aug 2013 A1
20130231640 Chen et al. Sep 2013 A1
Foreign Referenced Citations (45)
Number Date Country
19722932 Dec 1998 DE
10309558 Sep 2004 DE
202005010978 Oct 2005 DE
102005031711 Jun 2007 DE
202008004240 Jul 2008 DE
102007025714 Dec 2008 DE
10 2007 049430 Apr 2009 DE
10 2007 063294 Jul 2009 DE
102009036302 Feb 2011 DE
202010014723 Nov 2011 DE
0306262 Mar 1989 EP
1656914 May 2006 EP
1666077 Jun 2006 EP
1947167 Jul 2008 EP
2140958 Jan 2010 EP
2498829 Sep 2012 EP
2401879 Nov 2004 GB
0905341.4 Mar 2009 GB
2476133 Jun 2011 GB
1303971.4 Aug 2013 GB
WO 9831402 Jul 1998 WO
WO 0106047 Jan 2001 WO
WO 0138615 May 2001 WO
WO 0141819 Jun 2001 WO
WO 03046273 Jun 2003 WO
WO 2005018769 Mar 2005 WO
WO 2006021155 Mar 2006 WO
WO 2007029597 Mar 2007 WO
WO 2007046806 Apr 2007 WO
WO 2007078203 Jul 2007 WO
WO 2008010199 Jan 2008 WO
WO 2008024426 Feb 2008 WO
WO 2008098420 Aug 2008 WO
WO 2008100163 Aug 2008 WO
WO 2008101417 Aug 2008 WO
WO 2009141278 Nov 2009 WO
WO 2010123392 Oct 2010 WO
WO 2011073697 Jun 2011 WO
WO 2011076203 Jun 2011 WO
WO 2011101857 Aug 2011 WO
WO 2012075658 Jun 2012 WO
WO 2012106983 Aug 2012 WO
WO 2012127326 Sep 2012 WO
WO 2013123507 Aug 2013 WO
WO 2013123509 Aug 2013 WO
Non-Patent Literature Citations (3)
Entry
ohioline.osu.edu, ohio state, p. 1.
http://www.m2polymer.com/html/super—absorbent—fibers.html; Oct. 17, 2008 (see provided copy).
http://www.m2polymer.com/pdf/Tech%20Sheet—Oasis%20SAF%206mm—M2PT.pdf; Nov. 11, 2015.
Related Publications (1)
Number Date Country
20140257221 A1 Sep 2014 US